Replicate Bioscience is designing and delivering srRNA immunotherapies to revolutionize the practice of medicine and improve and save lives. Replicate applies advanced srRNA technology in its work to prevent drug resistance in cancers; this is the company's proprietary synthetic immune lethality approach.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/08/21 | $40,000,000 | Series A |
Apple Tree Partners | undisclosed |
